Secukinumab Shows Long-Term Bone Protection in Psoriatic Arthritis

Secukinumab preserved bone structure and controlled disease activity in psoriatic arthritis patients over 48 months, according to long-term phase IV study data.

Researchers tracked 32 adults with active psoriatic arthritis-mean age 56, 40.6% female-using high-resolution peripheral quantitative CT and hand MRI. The drug survival rate was 68.8%. Patients showed sustained improvement in disease activity, enthesitis, skin involvement, pain, and self-reported impact, while functional status remained stable.

Critically, bone density, cortical and trabecular microarchitecture, and biomechanical properties showed no significant deterioration. MRI confirmed persistently low inflammation, with only marginal increases in erosion and osteoproliferation scores.

These findings suggest secukinumab’s IL-17A inhibition delivers durable clinical control and long-term osteoprotection-key for preventing disability in psoriatic arthritis. No major safety concerns emerged during follow-up.